Related Experiment Video
Updated: May 2, 2026

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
Published on: October 5, 2020
Tumor suppressor role of phospholipase C epsilon in Ras-triggered cancers
Marta Martins1, Afshan McCarthy, Rhona Baxendale
1Division of Biosciences, Institute of Structural and Molecular Biology, and Department of Cell and Developmental Biology, Wolfson Institute for Biomedical Research, University College London, London WC1E 6BT, United Kingdom.
Abstract:
Phospholipase Cε (PLCε) has been characterized as a direct effector of Ras in vitro and in cellular systems; however, the role of PLCε in tumorigenesis and its link to Ras in this context remain unclear. To assess the role of PLCε in Ras-driven cancers, we generated two new mouse strains: one carrying a targeted deletion of Plce (Plce(-/-)) and the other carrying mutant alleles of Plce unable to bind to Ras (Plce(RAm/RAm)). The Plce(-/-) and, to a lesser degree, Plce(RAm/RAm) transgenic mice exhibited increased susceptibility to tumor formation in the two-stage skin carcinogenesis protocol, revealing a tumor suppressor function for this PLC. This result also suggests that in this context Ras binding in part regulates functions of PLCε. Although significant differences were not seen in the LSL-Kras(G12D) nonsmall cell lung carcinoma model, down-regulation of PLCε was found in animal tumors and in cellular systems following expression of the oncogenic Ras. An inhibitory impact of PLCε on cell growth requires intact lipase activity and is likely mediated by protein kinase C enzymes. Further cellular studies suggest involvement of histone deacetylase in the mechanism of PLCε down-regulation. Taken together, our results show a previously unidentified tumor suppressor role for this PLC in animal models and, together with observations of marked down-regulation in colorectal, lung, and skin tumors, suggest its use as a biological marker in cancer.
Insights
Phospholipase Cε (PLCε) acts as a tumor suppressor in Ras-driven cancers. Its downregulation in tumors suggests PLCε may serve as a valuable cancer biomarker.
Area of Science:
- Molecular Biology
- Oncology
- Biochemistry
Background:
- Phospholipase Cε (PLCε) is a known Ras effector, but its role in cancer and Ras-mediated tumorigenesis is unclear.
- Understanding PLCε's function in cancer is crucial for developing new therapeutic strategies.
Purpose of the Study:
- To investigate the role of PLCε in Ras-driven cancers.
- To determine if Ras binding influences PLCε's function in tumorigenesis.
- To explore PLCε's potential as a cancer biomarker.
Main Methods:
- Generated Plce knockout (Plce(-/-)) and Ras-binding deficient (Plce(RAm/RAm)) mouse models.
- Utilized a two-stage skin carcinogenesis protocol to assess tumor susceptibility.
- Analyzed PLCε expression in LSL-Kras(G12D) nonsmall cell lung carcinoma models and cellular systems.
- Investigated the impact of lipase activity and protein kinase C enzymes on PLCε's cell growth inhibition.
- Explored the involvement of histone deacetylase in PLCε downregulation.
Main Results:
- Plce(-/-) and Plce(RAm/RAm) mice showed increased susceptibility to skin tumors, indicating a tumor suppressor role for PLCε.
- Ras binding partially regulates PLCε's function in tumorigenesis.
- PLCε was significantly downregulated in animal tumors and cellular systems expressing oncogenic Ras.
- PLCε's inhibitory effect on cell growth requires intact lipase activity and involves protein kinase C.
- Histone deacetylase may contribute to PLCε downregulation.
Conclusions:
- PLCε possesses a previously unrecognized tumor suppressor function in animal models.
- Downregulation of PLCε in various tumors suggests its potential utility as a biological marker for cancer.
- Further research into PLCε's mechanisms in cancer is warranted.
Related Concept Videos
The Ras Gene
Ras is a...
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
The Ras Gene
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...

